Farmak has launched a new prescription medication on the Ukrainian market indicated for the treatment of type 2 diabetes mellitus, symptomatic chronic heart failure, and chronic kidney disease.
Diabetes mellitus remains one of the most prevalent chronic diseases globally. According to the International Diabetes Federation (IDF)*, approximately 589 million adults aged 20–79 are living with diabetes. More than 90% of these cases are type 2 diabetes. In 2024, diabetes was responsible for 3.4 million deaths worldwide—averaging one death every 9 seconds.
Type 2 diabetes, heart failure, and chronic kidney disease are closely interconnected. Impairment in one organ can negatively affect the function of others, complicating the progression of these conditions. For this reason, modern treatment approaches increasingly account for the interrelationship between metabolic, cardiovascular, and renal disorders.
The medication is available in the form of film-coated tablets. The new drug has also been included in the state reimbursement program, “Affordable Medicines” (*Dostupni Liky*). With a valid electronic prescription, patients can obtain the medication at no additional cost from participating pharmacies, subject to the program’s current reimbursement terms.